Skip to main content

Fibromyalgia/Pain

RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
overdose.narcotic.jpg

Gabapentin Implicated in Overdose Deaths

Jun 29, 2022

Recent FDA and MMWR warnings suggest that gabapentin was present and implicated in almost 10% of US overdose deaths between 2019 and 2020. This CDC report also stated that gabapentin was the cause of the death in half of these cases. 



Despite its FDA approval for the management of

Read Article
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Dr. John Cush @RheumNow( View Tweet )
Jun 18, 2022
Watch: Fatigue and Central Sensitization in Rheumatic Disease - We're sharing Philip Mease, MD presentation from the RheumNow Live 2022 meeting held in March.https://t.co/SFzsszL1aM https://t.co/DkxVPim9iU
Dr. John Cush @RheumNow( View Tweet )
Jun 15, 2022
cannabis,weed,marijuana

Is Pain Control by Cannabis an Option?

Jun 07, 2022

An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation. Studies of long-term outcomes and

Read Article
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2022
So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Jun 03, 2022
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
Jun 03, 2022
#EULAR2022 – Day 2 Report A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Dr. John Cush @RheumNow( View Tweet )
Jun 03, 2022
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
Jun 01, 2022
Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale. No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts @RheumNow
Jun 01, 2022
Amitriptyline and FDA Treatments for Fibromyalgia #MedEdhttps://t.co/zA4rycnHg4 https://t.co/TxD1jp6XGf
Dr. John Cush @RheumNow( View Tweet )
May 28, 2022
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

May 27, 2022

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?




  1. May 2022 EMA meeting the CHMP recommended new indications for

Read Article
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...https://t.co/u86Vd8bFGr#MedEdTwitter https://t.co/IpKqPoWM9R
Dr. John Cush @RheumNow( View Tweet )
May 26, 2022
Amitriptyline and FDA Treatments for Fibromyalgia #MedEdhttps://t.co/9PylojjL4S https://t.co/TxErjtU4eE
Dr. John Cush @RheumNow( View Tweet )
May 25, 2022
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush @RheumNow( View Tweet )
May 25, 2022
Long,covid

Long COVID Manifestations

MMWR
May 24, 2022

The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome.  Long COVID appears to affect up to 20% of those who survive COVID-19 infection. 

Read Article
pain.jpg

Amitriptyline and FDA Treatments for Fibromyalgia

May 23, 2022

Both old and newer pharmacological treatments for fibromyalgia are often promoted; but a recent systematic review and network meta-analysis showed that duloxetine had higher efficacy in pain and depression, while amitriptyline had higher efficacy in treating sleep, fatigue, and quality of life

Read Article
VA and Marketscan data analysis ~345k RA pts shows multimorbidity increased in RA; over-represented are cardiopulmonary, cardiometabolic, and mental health and chronic pain disorders (OR 1.17 - 2.96). https://t.co/awcGQPAdiN https://t.co/c4mLkDzvCM
Dr. John Cush @RheumNow( View Tweet )
May 23, 2022
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

May 20, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3
Dr. John Cush @RheumNow( View Tweet )
May 20, 2022
lumbar,spine,lbp,pain

Acute Inflammatory Responses Needed to Resolve Chronic Pain

May 16, 2022

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Read Article
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/qdC8VXC1ko https://t.co/C67sB6IFVL
Dr. John Cush @RheumNow( View Tweet )
May 15, 2022
2019 Gabapentin Rx=69 million; 7th most common Rx in USA. MMWR: 62,652 overdose deaths, 52% had Pos. gabapentin test. OD deaths w/ GAB involved usually involved illicitly manufactured fentanyls. GAB+Opioids=BAD COMBO! https://t.co/qQbPmwzAgJ

Dr. John Cush @RheumNow( View Tweet )

May 14, 2022
×